5-Year DiRECT Study: The Economic Case for Diabetes Remission

5-Year DiRECT Study: The Economic Case for Diabetes Remission

Read More
Full Text
2 weeks back

The landmark 5-year follow-up data from the DiRECT trial provides clear evidence regarding diabetes remission cost-effectiveness. Recent results show that an intensive weight management program significantly improves long-term health outcomes while reducing overall healthcare costs. Consequently, this intervention offers a sustainable solution for managing Type 2 Diabetes (T2DM) in primary care settings.



Sustained Weight Loss and Healthcare Savings


Over the five-year period, participants in the intervention arm achieved an average weight loss of 6.1 kg. Furthermore, approximately 10% of these individuals remained in remission from T2DM at the five-year mark. Notably, the total discounted healthcare cost savings per participant amounted to £2,091, excluding the initial intervention costs. Therefore, the program demonstrates both clinical efficacy and financial viability.



Analyzing Diabetes Remission Cost-Effectiveness


The researchers calculated an Incremental Cost-Effectiveness Ratio (ICER) of £13,541 per Quality-Adjusted Life-Year (QALY). This figure falls well below the standard willingness-to-pay thresholds used in many global healthcare systems. Moreover, the probability of the intervention being cost-effective reaches 98% at a £20,000 per QALY threshold. In contrast to standard care, this approach provides more life-years in remission and a better quality of life for patients.



Clinical Implications for Practice


Healthcare providers should consider total diet replacement and structured support as a primary strategy for early T2DM. This model reduces the medication burden, specifically for anti-hypertensive and anti-diabetic drugs. Additionally, the long-term reduction in primary and secondary care contacts offsets the initial costs of the formula diet and practitioner visits. Ultimately, prioritizing weight-mediated remission can transform the economic landscape of diabetes care.



Frequently Asked Questions


What is the DiRECT intervention?


The intervention uses the Counterweight-Plus program, which includes a low-energy formula diet (825–853 kcal/day) for 12–20 weeks, followed by food reintroduction and long-term weight maintenance support.


Is diabetes remission sustainable over 5 years?


Yes, the DiRECT trial showed that 10% of participants remained in remission at 5 years, with those maintaining significant weight loss having the highest success rates.



Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.



References


Davies A et al. Cost-effectiveness of the diabetes remission clinical trial (DiRECT)/Counterweight-Plus weight management programme, based on 5-year follow-up. Diabet Med. 2026 Mar 29. doi: 10.1111/dme.70306. PMID: 41904649.


Lean MEJ, et al. 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study. Lancet Diabetes Endocrinol. 2024;12(4):233-246.


Arpan, Singh N, et al. Achieving Diabetes Remission: Current Guidelines and Emerging Pharmacotherapies in India. J Assoc Physicians India 2025;73(10):83-86.

Login to continue

More from MedShots Daily

5-Year DiRECT Study: The Economic Case for Diabetes Remission
5-Year DiRECT Study: The Economic Case for Diabetes Remission

The 5-year DiRECT trial results prove that intensive weight management for T2DM remission is highly cost-effective, saving £2,091 in healthcare costs per pa...

2 weeks back

Read More
Full Text
Uni-leaflet Mitral Valve in Adults: Diagnosis and Management
Uni-leaflet Mitral Valve in Adults: Diagnosis and Management

A systematic review characterizing the clinical presentation, anatomy, and management of adult patients with rare uni-leaflet mitral valve (ULMV) anomaly....

Today

Read More
Full Text
TLR7 Signature Reveals Two Pathways of Triple-Negative Breast Cancer Progression
TLR7 Signature Reveals Two Pathways of Triple-Negative Breast Cancer Progression

New research identifies the TLR7 signature as a key marker for tumor innervation and progression pathways in triple-negative breast cancer (TNBC)....

Today

Read More
Full Text
CD8+ T Cells Identified as Key Drivers of Arterial Aging
CD8+ T Cells Identified as Key Drivers of Arterial Aging

New study identifies CD8+ T cells as the primary driver of arterial aging and stiffness, offering potential targets for treating vascular dysfunction....

Today

Read More
Full Text
Testosterone Combined with Multimodal Exercise Boosts Recovery in Spinal Cord Injury
Testosterone Combined with Multimodal Exercise Boosts Recovery in Spinal Cord Injury

A randomized trial shows that adding testosterone to multimodal exercise significantly improves lean mass and hemoglobin in adults with spinal cord injury....

Today

Read More
Full Text
Heterogeneity in European Pediatric Dietary Guidelines: A Call for Harmonization
Heterogeneity in European Pediatric Dietary Guidelines: A Call for Harmonization

A scoping review of 43 European countries reveals significant heterogeneity in pediatric dietary guidelines, pointing to a need for global harmonization....

Today

Read More
Full Text
Showing Page 1 of 1(5 items total)
Go to Page

"Wherever the art of Medicine is loved, there is also a love of Humanity."

— Hippocrates

made with❤️byOmnicuris